September
21,
2023
|
14:29 PM
Europe/Amsterdam
Bayer to collaborate with Hologic in breast cancer imaging
Not intended for U.S. and UK Media
Strategic expansion of Bayer’s portfolio in breast imaging / Companies to deliver innovative solutions on contrast-enhanced mammography (CEM) to imaging facilities / Collaboration to include education and hands-on training to support the safe and …
September
21,
2023
|
10:59 AM
Europe/Amsterdam
Agreement with UK-based NIAB to acquire their strawberry pipeline and commercial portfolio / Focus on large-scale professional strawberry growers to meet growing consumer and retail demand / The program will continue to be based in Kent,
September
21,
2023
|
08:59 AM
Europe/Amsterdam
Climate impacts estimated to have reduced farmer incomes by 15.7% on average over the past two years / Most pressing short-term challenges dominated by economic uncertainty and cost concerns / Yet 4 in 5 farmers have already taken or plan to take …
September
21,
2023
|
08:29 AM
Europe/Amsterdam
Bayer invests 250 million Euros in new production facility in Finland to accelerate global access to modern contraception
Not intended for U.S. and UK Media
The investment supports Bayer’s sustainability goal to help provide 100 million women in low- and middle-income countries with access to modern contraception by 2030 / The company’s facility in Turku will utilize automation, robotics, and digital …
September
20,
2023
|
17:59 PM
Europe/Amsterdam
Bayer issues 1.75 billion euro hybrid bond
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
New issue of two tranches with a non-call period of 5.25 and 8.25 years, respectively, combined with a tender offer for two of Bayer’s existing hybrid bonds
September
19,
2023
|
08:59 AM
Europe/Amsterdam
Leverkusen, September 19, 2023 – Dr. Jost Reinhard will take over as head of Bayer AG’s Investor Relations department effective October 1, 2023. The 51-year-old is currently responsible for Bayer’s Cell and Gene Therapy unit in the United States. …
September
18,
2023
|
08:59 AM
Europe/Amsterdam
Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator
Not intended for UK Media
Investigational VVD-130037 is highly specific, potent Kelch-like ECH Associated Protein 1 (KEAP1) activator developed for treatment of advanced solid tumors / Major milestone for Vividion’s chemoproteomics innovative technology platform / …
August
30,
2023
|
14:59 PM
Europe/Amsterdam
Bayer to invest EUR 220 million in new R&D facility at its Monheim site
Strong commitment to modern Crop Protection made in Europe:
Largest single investment in Crop Protection in Germany for 40 years / Focus on Environmental and Human Safety / State-of-the-art lab building and greenhouse / 5 floor main building; 28,000 m gross floor area / R&D facility offers space for 200 …
August
29,
2023
|
13:59 PM
Europe/Amsterdam
New agreement will focus on CRISPR applications for Bayer’s Preceon™ Smart Corn System / Collaboration builds on successful initial gene-editing partnership between the two companies that resulted in 27 novel traits being transferred into Bayer’s …
August
28,
2023
|
07:59 AM
Europe/Amsterdam
BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint
Not intended for UK Media
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year, exploratory clinical endpoints improved overall, with …
August
24,
2023
|
10:29 AM
Europe/Amsterdam
Additional studies with finerenone across a wide range of heart failure patients initiated
Not intended for U.S. and UK Media
Three new investigator-sponsored collaborative studies are funded by Bayer and will evaluate the efficacy and safety of finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist (MRA), in approximately 9,300 heart failure (HF) …